National Access Director - East

Your mission We are looking for creative, highly motivated individuals to help prepare for the successful launch of an innovative allogeneic T-cell immunotherapy in the US, Tabelecleucel (Tab-Cel) which is an investigational cell therapy for the treatment of Epstein Barr positive post-transplant lymphoproliferative disease. The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) resubmission for tabelecleucel (tab-cel® / Ebvallo) , setting a target action date of March 31, 2027, under the Prescription Drug User Fee Act (PDUFA). The National Access Director will play a critical role in preparing for launch and facilitating urgent access to Tab-cel once approved.…